Suceava buying MDMA pills

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Suceava buying MDMA pills

Atte Oksanen, Bryan L. Emily N. Weber, Ashley R. Taylor, Arthur L. Cantos, Barbara G. Amado, and K. Krueger, Michael B. First, Geoffrey M. Reed , and 7. Jonas Schemmel ,a , Benjamin G. Maier ,a , Renate Volbert , and 2 ,a. Antoni Ramos-Quiroga. Pergolizzi, and Letizia Caso. Houben, and Ray Bull. Ignacio Lijarcio , 2 , Francisco J. Useche , and 2. Angelica V. Hagsand, Daniel Pettersson, Jacqueline R. Evans, and Nadja Schreiber-Compo. Your request has been saved. The data we compile is analysed to improve the website and to offer more personalized services. By continuing to browse, you are agreeing to our use of cookies. For more information, see our cookies policy. Aguerrevere Vol. Assessing neighborhood disorder: Validation of a three-factor observational scale 81? Fisher Vol. Reed , and 7 Vol. Maier ,a , Renate Volbert , and 2 ,a Vol. Antoni Ramos-Quiroga Vol. Stop Harassment! Pergolizzi, and Letizia Caso Vol. Houben, and Ray Bull Vol. Child-to-parent Violence Offenders Specialists vs. Alami Vol. Useche , and 2 Vol. Evans, and Nadja Schreiber-Compo Vol. Your request has been saved Notify me when a new issue is online I have read and accept the information about Privacy. For more information, see our cookies policy Aceptar.

Suceava buying MDMA pills

Romania's Ministry of Health has proposed a dual-pricing system for pharmaceuticals as uncertainty regarding the updating of drug prices continues. The Romanian Ministry of Health MoH has unveiled a plan to introduce a dual-pricing system for medicines, while uncertainty persists around the updating of drug prices, resulting in supply problems. The dual-pricing system would mean that pharmacies contracted to the public health insurer would have lower prices, and another price catalogue would be in place for other pharmacies, with higher prices, which the MoH intends to be the prices that other EU member states would reference in international reference pricing. As well as the confusion and disruption being caused to the Romanian pharmaceutical market as the delay to the updating of prices continues, a more sustained uncertainty surrounds the potential consequences of a dual-pricing system. There is scepticism within the pharma industry concerning such a system's potential to have the effect the MoH desires — to limit parallel exports — since EU member states could opt to reference the prices in the lower-priced list anyway. Confusion persists around the updating of the prices of pharmaceuticals in Romania, following the recent announcement by the Romanian Ministry of Health MoH that it is preparing two separate national catalogues of medicine prices — effectively introducing a dual-pricing system — reports Romanian newspaper Adevarul. According to the source, pharmacies contracted to public health insurance funds will have lower prices, while those without such contracts will have higher prices. As a result of the delays and uncertainty around the updating of prices, there are significant problems of drug shortages in a number of regions, reports the source. Pharmacies with public health insurance contracts to have lower-priced drugs. According to a statement from an official from the MoH, quoted by Adevarul , the public national catalogue of medicinal products will include medicines approved under an order from the health minister to be marketed in pharmacies without contracts with health insurance funds, while the national catalogue of prices of medicines for human use CANAMED will have lower prices that will apply to pharmacies with such contracts. Reference prices of medicines on this catalogue will be approved following national debates, and, according to the MoH, these will come into force at the earliest opportunity. The source quotes the MoH official as stating that an additional catalogue was necessary because Romania is a reference country under international reference pricing IRP for 12 countries in the European Union and therefore changes in medicine prices in Romania would directly affect the prices in those nations. Therefore, the higher prices in the public national catalogue would be those officially applicable for IRP purposes. According to the source, Clara Popescu, the vice-president of the Romanian Association of Pharmacists CFR , stated that the two catalogues will set the maximum prices of medicines and expressed concern that producers would set drug prices based on this higher-priced catalogue, which would then force distributors to charge higher prices in turn to pharmacies and ultimately increase costs to patients. Popescu is reported as saying that the CFR intends to pressure the government to change the law. She stated further that she is sceptical about the expected completion date of the two catalogues and suggested that the beginning of July may be more realistic. This is in contrast with Alin Tucmeanu, the secretary of state in the MoH, who is quoted as saying that a completion date of 15 June is feasible. Innovative pharma chief sceptical that system would have desired effect. Dan Zaharescu, the director of the Romanian Association of International Medicine Manufacturers ARPIM , is quoted as saying that producers are worried about radical changes to the pricing system proposed by the MoH, adding that it is unclear what effect these will have on prices. Zaharescu is quoted as saying that ARPIM has warned that the consequence of the price updates could be that parallel exports would be boosted and more medicines in short supply in Romania. Furthermore, Zaharescu is quoted as saying that he finds it difficult to imagine that the authorities responsible for drug pricing in other EU countries would pay attention to the additional, higher-priced catalogue given that there is a catalogue in which the prices of drugs are basically the lowest in the entire EU. Pharmacies and wholesalers are reportedly opting not to buy new products, in fear of stock losses resulting from the expected imminent reduction in prices. Meanwhile, the online news service of Romanian news broadcaster Digi24 reports that pharmacies have had supply problems for weeks, and that cancer and HIV patients are being most affected by supply problems in hospitals. Digi24 also reports that more than 8, pharmacies in Romania do not have contracts with the Romanian National Health Insurance House CNAS; the central body of Romania's public health insurance funds , which the source predicts may face problems if the dual-pricing system comes into effect. Although the MoH has not been forthcoming about its rationale for its proposed introduction of dual pricing, it is clear that, as in the case of Spain — which faces sanctions from the European Commission as a result of its dual-pricing system — it is intended as a means to reduce the pressure on the Romanian public healthcare system caused by surging levels of parallel exports, resulting from the large difference between the prices of medicines in Romania, where they are generally very low, and many other EU member states. The intention is that medicines reimbursed by the CNAS will be subject to the lower prices, in order that reimbursement costs can be reduced, while these same medicines have another higher price that applies for IRP, which, in theory, would prevent even higher levels of parallel exporting. However, the head of ARPIM, Dan Zaharescu, is right to be sceptical about this proposal, since it has been seen in the past that EU member states tend to focus on prices that better suit their cost-containment goals — i. Same-Day Analysis Confusion persists over drug price updates in Romania as MoH announces plan for dual-pricing system. Published: 04 June Romania's Ministry of Health has proposed a dual-pricing system for pharmaceuticals as uncertainty regarding the updating of drug prices continues. IHS Life Sciences perspective Significance The Romanian Ministry of Health MoH has unveiled a plan to introduce a dual-pricing system for medicines, while uncertainty persists around the updating of drug prices, resulting in supply problems. Implications The dual-pricing system would mean that pharmacies contracted to the public health insurer would have lower prices, and another price catalogue would be in place for other pharmacies, with higher prices, which the MoH intends to be the prices that other EU member states would reference in international reference pricing. Outlook As well as the confusion and disruption being caused to the Romanian pharmaceutical market as the delay to the updating of prices continues, a more sustained uncertainty surrounds the potential consequences of a dual-pricing system. Pharmacies with public health insurance contracts to have lower-priced drugs According to a statement from an official from the MoH, quoted by Adevarul , the public national catalogue of medicinal products will include medicines approved under an order from the health minister to be marketed in pharmacies without contracts with health insurance funds, while the national catalogue of prices of medicines for human use CANAMED will have lower prices that will apply to pharmacies with such contracts. Additional catalogue necessary to avoid IRP issues The source quotes the MoH official as stating that an additional catalogue was necessary because Romania is a reference country under international reference pricing IRP for 12 countries in the European Union and therefore changes in medicine prices in Romania would directly affect the prices in those nations. Innovative pharma chief sceptical that system would have desired effect Dan Zaharescu, the director of the Romanian Association of International Medicine Manufacturers ARPIM , is quoted as saying that producers are worried about radical changes to the pricing system proposed by the MoH, adding that it is unclear what effect these will have on prices. Non-contracted pharmacies could face problems Digi24 also reports that more than 8, pharmacies in Romania do not have contracts with the Romanian National Health Insurance House CNAS; the central body of Romania's public health insurance funds , which the source predicts may face problems if the dual-pricing system comes into effect. Outlook and implications Although the MoH has not been forthcoming about its rationale for its proposed introduction of dual pricing, it is clear that, as in the case of Spain — which faces sanctions from the European Commission as a result of its dual-pricing system — it is intended as a means to reduce the pressure on the Romanian public healthcare system caused by surging levels of parallel exports, resulting from the large difference between the prices of medicines in Romania, where they are generally very low, and many other EU member states. Filter Sort. IHS Life Sciences perspective.

Suceava buying MDMA pills